Tag Archives: DAA

Are Patients Receiving the Latest Anti-HCV Drugs?

Posted on July 22, 2013 by Kristine Novak, PhD, Science Editor

Less than 20% of patients infected with the most common Hepatitis C virus (HCV) genotype receive the latest drugs approved by the US Food and Drug Administration (FDA), according to the August issue of Clinical Gastroenterology and Hepatology. This low … Continue reading →

Posted in Liver/Biliary, Technology | Tagged , , , , , , , , , , , , | 2 Comments

Is SVR12 As Good As SVR24?

Posted on June 17, 2013 by Kristine Novak, PhD, Science Editor

In patients with chronic Hepatitis C virus (HCV) infection, a sustained viral response to treatment regimens 12 weeks after therapy (SVR12) is a good indicator that the response will be maintained until week 24 (SVR 24), based on an analysis of … Continue reading →

Posted in Liver/Biliary, Technology | Tagged , , , , , , , , , , , , , | Leave a comment

New Ways to Study HCV, Genotypes 3 and 4

Posted on January 21, 2013 by Kristine Novak, PhD, Science Editor

Researchers can now study replication of Hepatitis C virus genotypes 3 and 4 in cultured cells, described in 2 articles in the January issue of Gastroenterology. These new tools will improve our understanding of how they cause liver disease, and … Continue reading →

Posted in Liver/Biliary, Technology | Tagged , , , , , , , , , , , , | 2 Comments

Can We Treat Chronic HCV Infection Without Interferon?

Posted on December 1, 2011 by Kristine Novak, PhD, Science Editor

A potent combination of 2 drugs that directly target the hepatitis C virus (HCV) is effective in patients with chronic infection, and doesn’t require interferon therapy, according to an article in the December issue of Gastroenterology. Patients infected with HCV … Continue reading →

Posted in Liver/Biliary, Technology | Tagged , , , , , , , , , | 1 Comment